Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP

  • R. E. Heikkila
  • I. Terleckyj
  • B. A. Sieber
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)


The DATATOP study is a clinical trial in which deprenyl, a selective inhibitor of monoamine oxidase-B (MAO-B), is being given to newly diagnosed Parkinsonian patients in an attempt to halt the progression of their disorder. In part, this is being done because of the working hypothesis than an MPTP-like molecule may be the cause of Parkinsonism, and deprenyl is known to protect against MPTP-induced dopaminergic neurotoxicity in experimental animals. In the present study we point out that several analogs of MPTP are good substrates not only for MAO-B but also for MAO-A. In addition, we point out that with long-term administration to rodents, deprenyl loses its selectivity as an inhibitor of MAO-B and also inhibits MAO-A. We believe that these observations have relevance for the DATATOP study.


Good Substrate Tyrosine Hydroxylase Activity MPTP Administration Dopaminergic Neurotoxicity Parkinson Study Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) (−)-Deprenyl leads to prolongation of 1-dopa efficacy in Parkinson’s disease. Mod Probl Pharmacopsychiatry 19:170–176.PubMedGoogle Scholar
  2. Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J (1985) Increased life expectancy resulting from addition of 1-deprenyl to madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64:113–127.PubMedCrossRefGoogle Scholar
  3. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546–4550.PubMedCrossRefGoogle Scholar
  4. Castagnoli N Jr, Chiba K, Trevor AJ (1985) Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 36:225–230.PubMedCrossRefGoogle Scholar
  5. Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120:574–578.PubMedCrossRefGoogle Scholar
  6. Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz DM, Kopin IJ (1984) Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol Bull 20:548–553.PubMedGoogle Scholar
  7. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD (1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) in monkeys. Eur J Pharmacol 106:209–210.PubMedCrossRefGoogle Scholar
  8. Davis GC, Williams AC, Markey SP, Ebert MH, Caine CD, Reichert CM, Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1:249–254.PubMedCrossRefGoogle Scholar
  9. Ekstedt B, Magyar K, Knoll J (1979) Does the B form selective monoamine oxidase inhibitor lose selctivity by long term treatment?. Biochem Pharmacol 28:919–923.PubMedCrossRefGoogle Scholar
  10. Fuller RW, Steranka LR (1985) Central and peripheral catecholamine depletion by 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in rodents. Life Sci 36:243–247.PubMedCrossRefGoogle Scholar
  11. Glover V, Sandier M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265:80–81.PubMedCrossRefGoogle Scholar
  12. Heikkila RE, Hess A, Duvoisin RC (1984a) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224:1451–1453.PubMedCrossRefGoogle Scholar
  13. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984b) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467–469.PubMedCrossRefGoogle Scholar
  14. Heikkila RE, Nicklas WJ, Vyas I, Duvoisin RC (1985) Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci Lett 62:389–394.PubMedCrossRefGoogle Scholar
  15. Heikkila RE, Kindt MV, Sonsalla PK, Giovanni A, Youngster SK, McKeown KA, Singer TP (1988) Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 85:6172–6176.PubMedCrossRefGoogle Scholar
  16. Hoppel CL, Grinblatt D, Kwok HC, Arora PK, Singh MP, Sayre LM, Greenblatt D (1987) Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+ ), the neurotoxic metabolite of MPTP. Biochem Biophys Res Commun 148:684–693.PubMedCrossRefGoogle Scholar
  17. Jarvis MF, Wagner GC (1985) Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine. Life Sci 36:249–254.PubMedCrossRefGoogle Scholar
  18. Kindt MV, Youngster SK, Sonsalla PK, Duvoisin RC, Heikkila RE (1988) Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2′Me-MPTP. Eur J Pharmacol 146:313–318.PubMedCrossRefGoogle Scholar
  19. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980.PubMedCrossRefGoogle Scholar
  20. Langston JW, Irwin I, Langston EB, Forno LS (1984) Pargyline prevents MPTP-induced Parkinsonism in primates. Science 225:1480–1482.PubMedCrossRefGoogle Scholar
  21. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature 311:464–467.PubMedCrossRefGoogle Scholar
  22. Mayer RA, Walters AS, Heikkila RE (1986) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration to C57-black mice leads to parallel decrements in neostriatal dopamine content and tyrosine hydroxylase activity. Eur J Pharmacol 120:375–377.PubMedCrossRefGoogle Scholar
  23. Mizuno Y, Sone N, Saitoh T (1987) Effects of l-methyl-4-phenyl-l,2,3,6-tetrahyd-ropyridine and l-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J Neurochem 48:1787–1793.PubMedCrossRefGoogle Scholar
  24. Mizuno Y, Sone N, Suzuki K, Saitoh T (1988) Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain. J Neurol Sci 86:97–110.PubMedCrossRefGoogle Scholar
  25. Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine. Life Sci 36:2503–2508.PubMedCrossRefGoogle Scholar
  26. Ofori S, Heikkila RE, Nicklas WJ (1989) Attenuation by dopamine uptake blockers of the inhibitory effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and some of its analogs on NADH-linked metabolism in mouse neostriatal slices. J Pharmacol Exp Ther 251:258–266.PubMedGoogle Scholar
  27. Oreland L, Arai Y, Stenstrom A (1983) The effect of deprenyl (selegiline) on intra-and extraneuronal dopamine oxidation. Acta Neurol Scand [Suppl] 95:81–85.CrossRefGoogle Scholar
  28. Parkinson Study Group (1989a) Effect of deprenyl on the progession of disability in early Parkinson’s disease. N Engl J Med 321:1364–1371.CrossRefGoogle Scholar
  29. Parkinson Study Group (1989b) DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 46:1052–1060.CrossRefGoogle Scholar
  30. Ramsay RR, Singer TP (1986) Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 261:7585–7587.PubMedGoogle Scholar
  31. Ramsay RR, Salach JI, Singer TP (1986) Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP +. Biochem Biophys Res Commun 134:743–748.PubMedCrossRefGoogle Scholar
  32. Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with 1-deprenyl. J Neurochem 46:1356–1365.CrossRefGoogle Scholar
  33. Salach JI, Singer TP, Castagnoli N Jr, Trevor A (1984) Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem Biophys Res Commun 125:831–835.PubMedCrossRefGoogle Scholar
  34. Schulz R, Antonin K-H, Hiffmann E, Jedrychowski M, Nilsson E, Schick C, Bieck PR (1989) Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 46:528–536.PubMedCrossRefGoogle Scholar
  35. Sonsalla PK, Heikkila RE (1986) The influence of dose and dosing interval on M PTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 129:339–345.PubMedCrossRefGoogle Scholar
  36. Sundstrom E, Stromberg I, Tsutsumi T, Olson L, Jonsson G (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405:26–38.Google Scholar
  37. Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245:519–522.PubMedCrossRefGoogle Scholar
  38. Vyas I, Heikkila RE, Nicklas WJ (1986) Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem 46:1501–1507.PubMedCrossRefGoogle Scholar
  39. Youngster SK, Sonsalla PK, Heikkila RE (1987) Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 48:929–934.PubMedCrossRefGoogle Scholar
  40. Youngster SK, Sonsalla PK, Sieber BA, Heikkila RE (1989a) Structure activity of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced neurotoxicity I. Evaluation of the biological activity of MPTP analogs. J Pharmacol Exp Ther 249:820–828.Google Scholar
  41. Youngster SK, Nicklas WJ, Heikkila RE (1989b) Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs. J Pharmacol Exp Ther 249:829–835.Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • R. E. Heikkila
    • 1
  • I. Terleckyj
    • 1
  • B. A. Sieber
    • 1
  1. 1.Department of NeurologyUMDNJ-Robert Wood Johnson Medical SchoolPiscatwayUSA

Personalised recommendations